- Total revenues of €127.0 million compared to €116.6 million in the first nine months of 2024
- Cash and cash equivalents of €143.5 million at end of September 2025
- Financial flexibility enhanced with successful debt refinancing in October 2025 [1]
- Lyme disease Phase 3 study VALOR on track
- Updated 2025 financial outlook confirmed[1]
Saint-Herblain (France), November 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of the year, ended September 30, 2025. The condensed consolidated interim financial results are available on the Company’s website (Financial Reports – Valneva).
To access the full release, please click on the PDF below.
[1] Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates – Valneva